-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 11, 2022, Amgen and Arrakis Therapeutics announced a research collaboration to discover and develop RNA-degrading therapeutics for a range of difficult-to-drug targets across multiple therapeutic areas
This class of innovative targeted RNA-degrading therapies consists of small-molecule drugs that selectively destroy RNAs encoding disease-causing proteins by inducing their proximity to nucleases
Most of the drugs currently developed for protein targets target a few types of proteins (such as receptor proteins)
Arrakis is taking multiple approaches to establish a new paradigm for small molecule drug discovery targeting multiple mechanisms of the RNA life cycle
Arrakis is taking multiple approaches to establish a new paradigm for small molecule drug discovery targeting multiple mechanisms of the RNA life cycle
▲Schematic diagram of Arrakis' RNA-targeting small molecule drug platform (Image source: Arrakis authorized to use)
▲Schematic diagram of Arrakis' RNA-targeting small molecule drug platform (Image source: Arrakis authorized to use)The Induced Proximity Platform, which Amgen has established, enables the development of multispecific molecules
Under the terms of the agreement, Arrakis will be responsible for research activities to discover small-molecule compounds that bind to RNA against a broad range of targets nominated by Amgen
"Targeted RNA degradation is an exciting field that is pushing the boundaries of drug discovery and design
Original in English: https://investors.
https://investors.
amgen.
com/news-releases/news-release-details/amgen-and-arrakis-therapeutics-announce-multi-target